Hepatitis C virus (HCV) is the RNA virus responsible for the hepatitis C disease. Total global HCV prevalence is estimated at 2.5% (177.5 million of HCV infected adults), ranging from 2.9% in Africa to 1.3% in Americas (1). In European Union number of viremic HCV cases of HCV is estimated to be more than 3.2 million, while in Poland exceeds 200,000 with around 80% being not aware of their infection (2, 3). Chronic hepatitis C infection may be associated with several features of autoimmunity, autoimmune hepatitis being one of them. Hepatitis C is also associated with other autoimmune diseases, such as autoimmune thyroiditis, lichen ruber planus, and membranous glomerulonephritis. One of the indicators of autoimmune disease is the presence of autoantibodies in serum and among them, antinuclear antibodies (ANA) – usually present in serum of patients with autoimmune hepatitis. Data indicate that serum ANA are positive in 6% general population and even more among women and over 50 years old populations (4). However, reported incidence rates of AIH are around 1 per 100,000 population per year. Prevalence of serum autoantibodies in chronic hepatitis C patients is known to be higher than that in the general population. Data indicate that ANA may be positive in 9% of the chronic hepatitis C patients (5). Nevertheless, isolated ANA positivity is not a factor in chronic HCV disease progression and does not affect the treatment response (6). Because of that, the coincidence of chronic hepatitis C with an autoimmune hepatitis usually have to be confirmed by liver biopsy and characteristic histological features in the bioptate. During the time of interferon-based antiviral therapies, hepatitis C treatments in patients with AIH were extremely difficult to perform, as interferon could lead to an exacerbation of the coincident autoimmune disease, or even induce another one (7). In these cases, a prophylactic immunosuppression had to be started before initiation of interferon therapy. Even then, the risk of AIH exacerbation was high and many clinicians were resigning from treating such patients for HCV infection. Nowadays, highly specific and effective therapeutic options are available, in the form of direct antiviral agents (DAA) against hepatitis C. However, the data about HCV treatment with DAA in patients with autoimmune hepatitis are still scarce. Potential pitfalls of AIH therapy in chronic hepatitis C patients with DAA include a deregulation of immunity after rapid clearance of HCV-RNA, but also potential drug to drug interactions with DAA and immunosuppressive therapy. We present two cases of patients with coincidence of autoimmune hepatitis and HCV infection treated with DAA therapy. Both cases share similarity in AIH type and advancement, used immunosuppressive therapy but also DAA regiment. On the other hand, one was complicated with severe exacerbation while in second no complications during DAA therapy were observed.